Mibefradil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Sheng Shi, M.D. [2]

Mibefradil

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a607007
Routes of administration	Oral
ATC code	C08CX01 (WHO)
Legal status
Legal status	Withdrawn from market
Identifiers
IUPAC name (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
CAS Number	116644-53-2 Y
PubChem CID	60662
DrugBank	DB01388 N
ChemSpider	54673 N
UNII	27B90X776A
KEGG	D08217 Y
ChEMBL	ChEMBL45816 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C29H38FN3O3
Molar mass	495.63 g/mol
3D model (JSmol)	Interactive image
SMILES CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
InChI InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1 N Key:HBNPJJILLOYFJU-VMPREFPWSA-N N
NY (what is this?)  (verify)

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers. It is nonselective. On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.